tbuckley/cabot-search huggingface dataset:
P08.34 Overall survival of primary high-grade gliomas of supra- and infratentorial midline structures
Authors: C. A. Hamisch, S. Kellermann, T. Blau, S. Grau, R. Goldbrunner, M. I. Ruge
Journal: Neuro-Oncology (2016)

AbstractObjective:In literature recent and roubust data on the prognosis of patients with high grade gliomas (HGG) of WHO III° and IV° stratified by resectability, molecular features and different treatment modalities are available. However, little is known about outcome of patients with HGG´s located in supra- and infratentorial midline structures like corpus callosum, basal ganglia and brainstem. In this study we evaluate overall survival (OS) and influencing factors of patients with de novo HGG specifically in those structures.Patients and Methods:In a single center retrospective analysis we screened our database for all adult patients with primary HGG in midline structures diagnosed by stereotactic biopsy (SB) between January 1996 and March 2015. We evaluated OS and analyzed factors (MGMT status, treatment after SB, age, gender, Karnofsky Score (KPS), localization) influencing OS using Whitney-Mann-U and Chi-square test as well as cox regression analysis.Results.122 patients with HGG receiving stereotactic biopsy procedures (median age: 56.3 (22–82) years; median KPS: 80 (50–100)%. Histology revealed glioma WHO III° in 31.1% and WHO IV° in 68.9%. Lesions were localized in corpus callosum (50.0%), basal ganglia (18.9%), thalamus (9.0%), pineal region (2.5%), sella (0.8%), brainstem (18.9%). Median overall survival (mOS) was 6.3 months (95% CI, 3.6–9.0%), for WHO III°: 13.6 months (95% CI 5.6–21.6) and WHO IV°: 4.9 months (95 % CI, 3.2–6.6). Patients were treated as follows: no specific tumor therapy (13.1%, 2 WHO III° and 15 WHO IV°; mOS 1.1 months) or various Tumor specific therapy regimens (WHO III° 34 (32.4%) patients mOS 15.5 month [95% CI 7.4–23.6]), (WHO IV° 65 (61.9%) patients mOS 10.6 months). In 6 patients (5.7%) the type of adjuvant therapy is unknown. MGMT promotor methylation status was available for 46 tumor treated patients (18 WHO III°, 28 WHO IV°). mOS of patients with WHO IV tumors was significantly worse than WHO III° (p<0.0001). Any tumor specific treatment improved survival significantly (p=0.005). Poor condition (KPS<70) and no tumor specific therapy were the significant factors for poor OS in multivariate analysis (adjusted HR 1.88 CI95% 1.03–3.92 p=0.04 and 11.09 CI95% 5.24–23.35 p<0.0001 respectively).Conclusion:Overall survival de novo HGG’s especially of WHO IV located in midline structures is poor. Specific tumor treatment improves survival significantly. Treatment decision should be based on the patient’s clinical status for the best quality of life.
Further Studies on Urethane-Induced Pulmonary Tumors
Authors: Paul S. Henshaw, Henry L. Meyer
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Further Studies on Urethane-Induced Pulmonary Tumors Paul S. Henshaw, Paul S. Henshaw Search for other works by this author on: Oxford Academic PubMed Google Scholar Henry L. Meyer Henry L. Meyer Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 5, Issue 6, June 1945, Pages 415–417, https://doi.org/10.1093/jnci/5.6.415 Published: 01 June 1945
Monitoring of ADAMTS13 in Patients with Thrombotic Thrombocytopenic Purpura: Prediction of Response to Therapy, Risk of Relapse, and Long- Term Outcome.
Authors: Paul Knoebl, Silvia Koder, Peter Schellongowski, Peter Distelmaier, Peter Quehenberger, Ingrid Pabinger, Bernd Jilma
Journal: Blood (2008)
Hydroxyurea Treatment Is Associated with Elevated Serum Erythropoietin Concentration but Suppressed Global Hypoxic Transcriptional Responses in Sickle Cell Disease
Authors: Xu Zhang, Wei Zhang, Binal Shah, Galina Miasnikova, Adelina Sergueeva, Tatiana Ammosova, Xiaomei Niu, Mehdi Nouraie, Sergei Nekhai, Roberto F. Machado, Joe G.N. Garcia, Mark T. Gladwin, Oswaldo L Castro, Victor R. Gordeuk
Journal: Blood (2015)
Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma
Authors: Khaled M Ramadan, Joseph M. Connors, Abdul Al-Tourah, Randy D. Gascoyne, Kevin W. Song, Michael J. Barnett, Stephen H. Nantel, Thomas J. Nevill, John D. Shepherd, Heather J. Sutherland, Julye Lavoie, Donna L. Forrest, Donna E. Hogge, Nicholas Voss, Ryan Brinkman, Yasser R. Abou Mourad, Maryse M. Power, Sujaatha Narayanan, Clayton A. Smith, Cynthia L. Toze
Journal: Blood (2008)
Erratum to: Involvement of GTA protein NC2beta in Neuroblastoma pathogenesis suggests that it physiologically participates in the regulation of cell proliferation
Authors: Cinzia Di Pietro, Marco Ragusa, Davide Barbagallo, Laura R Duro, Maria R Guglielmino, Alessandra Majorana, Veronica Giunta, Antonella Rapisarda, Elisa Tricarichi, Marco Miceli, Rosario Angelica, Agata Grillo, Barbara Banelli, Isabella Defferari, Stefano Forte, Alessandro Laganà, Camillo Bosco, Rosalba Giugno, Alfredo Pulvirenti, Alfredo Ferro, Karl H Grzeschik, Andrea Di Cataldo, Gian P Tonini, Massimo Romani, Michele Purrello
Journal: Molecular Cancer (2008)
Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study
Authors: Steven Le Gouill, Mary Callanan, Elizabeth Macintyre, marie-Hélène delfau-Larue, Caroline bodet-Milin, Michel Meignan, Anne Moreau, Alexandra Travers-Glehen, Marie-christine Béné, Corinne Haouin, Remy Gressin, Rene-Olivier Casasnovas, Vincent Ribrag, Gandhi Damaj, Emmanuel Gyan, Lucie Oberic, Krimo Bouabdallah, Catherine Thieblemont, Olivier Hermine
Journal: Blood (2012)
KEYNOTE-170: Phase 2 study of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS)
Authors: J.-M. Michot, P. Armand, W. Ding, V. Ribrag, B. Christian, P. Marinello, S. Chlosta, Y. Zhang, M. Shipp, P.L. Zinzani
Journal: Annals of Oncology (2016)
Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial
Authors: J. Taieb, K. Le Malicot, R. Balogoum, J. Tabernero, E. Mini, G. Folprecht, J.-L. van Laethem, J.-F. Emile, C. Mulot, S. Fratté, C.-B. Levaché, L. Saban-Roche, J. Thaler, L. Nørgård Petersen, E. Sanchez, J. Bridgewater, G. Perkins, C. Lepage, A. Zaanan, P. Laurent-Puig
Journal: Annals of Oncology (2016)
The Tumor Microenvironment at a Turning Point—Knowledge Gained Over the Last Decade, and Challenges and Opportunities Ahead: A White Paper from the NCI TME Network
Authors: Yves A. DeClerck, Kenneth J. Pienta, Elisa C. Woodhouse, Dinah S. Singer, Suresh Mohla
Journal: Cancer Research (2017)

Over the past 10 years, the Tumor Microenvironment Network (TMEN), supported by the NCI (Bethesda, MD), has promoted collaborative research with the explicit goal of fostering multi-institutional and transdisciplinary groups that are capable of addressing complex issues involving the tumor microenvironment. The main goal of the TMEN was to generate novel information about the dynamic complexity of tumor-host interactions in different organ systems with emphasis on using human tissues and supplemented by experimental models. As this initiative comes to a close, members of the TMEN took time to examine what has been accomplished by the Network and importantly to identify the challenges and opportunities ahead. This consensus document summarizes for the broader scientific community discussions that occurred at the two final meetings of the TMEN in 2015 and 2016. Cancer Res; 77(5); 1051-9. ©2017 AACR.
Meta-Analysis of the Risk of Subsequent Mood Episodes in Bipolar Disorder
Authors: Joaquim Radua, Heinz Grunze, Benedikt L. Amann
Journal: Psychotherapy and Psychosomatics (2017)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Reported relapse and recurrence rates in bipolar disorder (BD) differ significantly between studies. Most data originate from highly selective patients participating in sponsored randomized controlled trials with narrow inclusion criteria. To estimate the true risk of a subsequent mood episode (SME) under real-world conditions, we conducted a meta-analysis of rates of SME as reported in naturalistic BD studies. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; PubMed, ScienceDirect, Scopus, and Web of Knowledge were searched until July 2015. Studies reporting the time until the emergence of an SME, from which individual data or Kaplan-Meier plots with censors marked could be retrieved, were included. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Twelve studies comprising 5,837 patients met the inclusion criteria. The median time to an SME in adults after an index episode was 1.44 years. The risk of an SME was 44% during the first year. Not having a SME during this first year lowered this risk to 19% in the second year. The risk was higher in bipolar II disorder (BD-II) than in bipolar I disorder (BD-I; HR = 1.5). In BD-I, the risk of a subsequent manic, mixed, or depressive mood episode was higher after an index episode of the same polarity (HR = 1.89-5.14). The overall risk of an SME was higher in patients with persisting subsyndromal symptoms (HR = 2.17). &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; The data from this study provide a more reliable estimate of the risk of an SME in BD in real-world settings. Further research into the longitudinal course of BD-II is warranted to confirm its role as a risk factor for SME.
GATA4-dependent organ-specific endothelial differentiation controls liver development and embryonic hematopoiesis
Authors: Cyrill Géraud, Philipp-Sebastian Koch, Johanna Zierow, Kay Klapproth, Katrin Busch, Victor Olsavszky, Thomas Leibing, Alexandra Demory, Friederike Ulbrich, Miriam Diett, Sandhya Singh, Carsten Sticht, Katja Breitkopf-Heinlein, Karsten Richter, Sanna-Maria Karppinen, Taina Pihlajaniemi, Bernd Arnold, Hans-Reimer Rodewald, Hellmut G. Augustin, Kai Schledzewski, Sergij Goerdt
Journal: Journal of Clinical Investigation (2017)

Microvascular endothelial cells (ECs) are increasingly recognized as organ-specific gatekeepers of their microenvironment. Microvascular ECs instruct neighboring cells in their organ-specific vascular niches through angiocrine factors, which include secreted growth factors (angiokines), extracellular matrix molecules, and transmembrane proteins. However, the molecular regulators that drive organ-specific microvascular transcriptional programs and thereby regulate angiodiversity are largely elusive. In contrast to other ECs, which form a continuous cell layer, liver sinusoidal ECs (LSECs) constitute discontinuous, permeable microvessels. Here, we have shown that the transcription factor GATA4 controls murine LSEC specification and function. LSEC-restricted deletion of Gata4 caused transformation of discontinuous liver sinusoids into continuous capillaries. Capillarization was characterized by ectopic basement membrane deposition, formation of a continuous EC layer, and increased expression of VE-cadherin. Correspondingly, ectopic expression of GATA4 in cultured continuous ECs mediated the downregulation of continuous EC-associated transcripts and upregulation of LSEC-associated genes. The switch from discontinuous LSECs to continuous ECs during embryogenesis caused liver hypoplasia, fibrosis, and impaired colonization by hematopoietic progenitor cells, resulting in anemia and embryonic lethality. Thus, GATA4 acts as master regulator of hepatic microvascular specification and acquisition of organ-specific vascular competence, which are indispensable for liver development. The data also establish an essential role of the hepatic microvasculature in embryonic hematopoiesis.
ACTR-35. REPRESENTATION OF PATIENTS WITH CNS DISEASE IN PHASE I CLINICAL TRIALS: SINGLE CENTER EXPERIENCE
Authors: Manjari Pandey, Matthew Ballo
Journal: Neuro-Oncology (2016)

Phase I clinical trials largely target patients with advanced or metastatic tumors. However patients with active brain metastases are often excluded from such studies that are designed to test new anticancer agents. We evaluated representation and outcomes of patients with brain metastases in clinical trials for advanced solid tumors in the New Therapeutics Program (phase I) at the West Cancer Center. We identified all patients that were enrolled in phase I studies for advanced solid tumors at the West Cancer Center from January 2010 to May 2016 and had a secondary diagnosis of “secondary malignant neoplasm of the brain and spinal cord”. We conducted a retrospective chart review of these patients to get information on the demographic, clinical and tumor characteristics as well as type of treatment and outcomes. We identified 241 patients treated on phase I clinical trial for advanced solid tumors, of which 36 patients were diagnosed with CNS metastases. Patients diagnosed post enrolment were excluded from the analysis that left just 9 patients that were enrolled in trial with known CNS metastases. 4 of these patients were enrolled in trials for lung cancer and 5 in basket trials. 7 of these patients were enrolled within the last 2 years. Patients with CNS metastases continue to be under-represented in clinical trials for advanced solid tumors. However with the availability of molecular profiling, “basket trials” and targeted therapy are new options for these patients. There is an increasing trend towards enrolment of these patients in early phase studies of drug development
The Precautionary Principle and the Tolerability of Blood Transfusion Risks
Authors: Koen Kramer, Hans L. Zaaijer, Marcel F. Verweij
Journal: The American Journal of Bioethics (2017)

Tolerance for blood transfusion risks is very low, as evidenced by the implementation of expensive blood tests and the rejection of gay men as blood donors. Is this low risk tolerance supported by the precautionary principle, as defenders of such policies claim? We discuss three constraints on applying (any version of) the precautionary principle and show that respecting these implies tolerating certain risks. Consistency means that the precautionary principle cannot prescribe precautions that it must simultaneously forbid taking, considering the harms they might cause. Avoiding counterproductivity requires rejecting precautions that cause more harm than they prevent. Proportionality forbids taking precautions that are more harmful than adequate alternatives. When applying these constraints, we argue, attention should not be restricted to harms that are human caused or that affect human health or the environment. Tolerating transfusion risks can be justified if available precautions have serious side effects, such as high social or economic costs.
OS2.1 Immune responses to a mutation-specific peptide vaccine targeting IDH1R132H in patients with IDH1R132H-mutated gliomas
Authors: T. Bunse, L. Bunse, F. Sahm, T. Omokoko, S. Stevanovic, A. von Deimling, U. Sahin, M. Schmitt, W. Wick, M. Platten
Journal: Neuro-Oncology (2016)

Immunotherapeutic concepts for brain tumors have been hampered by lack of selective measures to target the CNS and lack of truly tumor-specific antigens. But the concept of an immune privileged CNS has to be questioned due to survey of the brain by specific T-cells, CNS autoimmunity and presence of lymphatics. As tumor-specific antigens, mutated antigens have come into focus for all tumor entities. Mutations in the gene for isocitrate dehydrogenase 1 frequently occur in diffuse gliomas, mostly astrocytomas, resulting in a point mutation (mostly IDH1R132H). IDH1R132H is an ideal tumor-specific antigen, because it is tumor-specific, homogenously expressed and considered a driving mutation in glioma. Preclinical studies have shown that mutation-specific Th cell responses spontaneously occur in patients with IDH1 -mutated gliomas and that a peptide vaccine encoding IDH1R132H is therapeutic in a humanized mouse tumor model. Based on these data we have initiated a multicenter, first-in-man, phase I clinical vaccine trial, which is planned to enroll 39 patients with newly diagnosed malignant IDH1R132H+ astrocytomas at eight German sites: NOA-16 (NCT02454634). The vaccine is made of an IDH1R132H peptide emulsified in mineral oil and administered with topical imiquimod. Vaccination is implemented into primary standard therapy. Primary end points are safety and immunogenicity as measured by IDH1R132H-specific antibodies and T cell responses. As of March 2016, 13 patients have been enrolled in the trial; no severe adverse events have been reported. We report here on 3 patients treated with the vaccine on a compassionate use basis. No patient experienced a regime-limiting toxicity as defined in the trial protocol. Two patients received all 8 doses of the vaccine; both developed IDH1-specific antibody responses, which were mutation-specific early after vaccination. Of these, one patient developed a vaccination-induced mutation-specific cellular response. The second patient had a high baseline mutation-specific T cell response, which was temporarily boosted by the vaccine. IFN-γ catch assays from PBMCs of this patient revealed a Th cell-mediated response. To identify and clone IDH1R132H-specific TCR(s) for adoptive T cell therapy, single T cells from this patient specifically responding to IDH1R132H were sorted and subjected to TCR sequencing. 11 TCRs have been identified so far and will be cloned and validated. In summary, we demonstrate for the first time the induction of a mutation-specific humoral and cellular immune response to the IDH1R132H neoepitope after peptide vaccination of patients with IDH1R132H-mutated gliomas. The ongoing trial will analyze safety and immunogenicity of the vaccine in a defined patient cohort, which also allows for collecting data on therapeutic efficacy.
Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents
Authors: P. Grassi, L. Doucet, P. Giglione, V. Grünwald, B. Melichar, L. Galli, U. De Giorgi, A. Guida, C. Ortega, M. Santoni, A. Bamias, E. Verzoni, L. Derosa, H. Studentova, L. Porcu, F. de Braud, C. Porta, B. Escudier, G. Procopio
Journal: Annals of Oncology (2016)
It's not the quality but the quantity: tumor mutation spectrum and response to neoadjuvant therapy in triple negative breast cancer
Authors: S. Di Cosimo, M. Dugo, V. Appierto, S. Cavalieri, V. Angeloni, G. Galli, G. Bregni, V. Cappelletti, B. Paolini, F. Perrone, P. Tiberio, F. de Braud
Journal: Annals of Oncology (2016)
The incidence of serious venous thromboembolic events in 1157lung cancer patients
Authors: Bohdan Kadlec, Jana Skřičková, Irena Vašutová, Marcela Tomíšková, Lenka Babičková, Jana Kaplanová
Journal: European Respiratory Journal (2008)

The incidence of serious venous thromboembolic events in 1157
lung cancer patients over the period of four years is analyzed.
Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.
Authors: Dharminder Chauhan, Ajita Singh, Mugdha Velankar, Teru Hideshima, Huib Ovaa, Celia Berkers, Giada Bianchi, Roberto Sitia, Nikhil C. Munshi, Paul Richardson, Michael A. Palladino, Kenneth C. Anderson
Journal: Blood (2006)
Phase 1 study of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres in patients (pts) with renal cell carcinoma (RCC): RESIRT
Authors: P. de Souza, P. Aslan, W. Clark, M. Patel, J.A. Vass, D. Cade, S.J. de Silva
Journal: Annals of Oncology (2016)
Targeting Hematopoietic Cells Using a Blimp-1 Promoter Helper Dependent Adenoviruses.
Authors: Chang-Xin Shi, Xiao-Yan Wen, Ding-Yan Wang, Bo Gao, Gillian Sleep, Li-Hua Zhuang, Zhi-Hua Li, Mary M. Hitt, A. Keith Stewart
Journal: Blood (2004)
Global phase 3, randomized, double-blind, placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma
Authors: E. Van Cutsem, A.E. Hendifar, M. Reni, W.P. Harris, M. Ducreux, A. Bullock, P. Corrie, V. Heinemann, T. Seery, D. Chondros, L. Zheng
Journal: Annals of Oncology (2016)
EPID-11. THE CONTRIBUTION OF THE rs55705857 G ALLELE TO FAMILIAL CANCER RISK USING THE UTAH POPULATION DATABASE
Authors: Sarah Hummel, Wendy Kohlmann, Thomas Kollmeyer, Robert Jenkins, Joshua Sonnen, Howard Colman, Diana Abbott, Lisa Cannon-Albright, Adam Cohen
Journal: Neuro-Oncology (2016)

IDH1/2 mutated glioma is associated with the presence of a germline risk variant, the rs55705857 G allele. The Utah Population Database (UPDB) is a unique prospective resource for evaluating cancer risk in related individuals. We aimed to determine the risk of glioma and other cancers in relatives of patients with IDH1/2 mutant glioma based on rs55705857 alleles. Patients with IDH1/2 mutant or 1p/19q co-deleted glioma were identified. Samples of either blood or tumor were obtained from the Huntsman Cancer Institute Cancer Clinical Research Database. For those people with DNA available from both blood and tumor, we compared the genotyping results to determine if tumor accurately represents rs55705857 genotype. One hundred and two individuals were genotyped and linked to the UPDB. We determined congruence between somatic and germline samples and estimated the relative risk (RR) to first and second-degree relatives of G allele carriers to develop cancers associated with IDH1/2 mutations. Somatic DNA had 85.7 % Sensitivity (CI 57.2%-98.2%) and 95.8 % Specificity (CI 78.9%-99.89%) for the rs55705857 G allele. Forty-one patients linked to three-generation pedigrees in the UPDB. First-degree relatives of rs55705857 G allele carrier patients are at significantly increased risks for developing any cancer (RR = 1.72, p=0.045, CI 1.02-2.94), and specifically oligodendroglioma (RR= 57.61, p=0.017, CI 2.96-320.98) or prostate cancer (RR= 4.10, p=0.008, CI 1.62-9.58), but relatives of people without the rs55705857 G allele are not at increased risk. Second-degree relatives of G allele carriers also had an overall increased risk for developing cancer (RR = 1.50, p=0.007, CI 1.15-2.01). Tumor DNA accurately reflects rs55705857 genotype. The G allele at this locus confers an increased risk of all cancers and of oligodendroglioma in relatives. No increased cancer or brain tumor risk was seen in family members of people without the G allele SNP rs55705857.
Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.
Authors: Issa Khouri, Roland L Bassett, Yvonne Hsu, Timothy Dickason, Sandra Acholonu, Robyn Harrell, Grace-Julia Okoroji, Leandro de Padua Silva, Martin J. Korbling, Amin M. Alousi, Chitra Hosing, Uday Popat, Sergio A. Giralt, Partow Kebriaei, Muzaffar H. Qazilbash, Celina Ledesma, Michael J. Keating, Richard E. Champlin, Carlos Bueso-Ramos
Journal: Blood (2008)
Expression of JL1 Antigen in Acute Leukemia and Myelodysplastic Syndrome
Authors: Han-Seung Park, Je-Hwan Lee, Jung-Hee Lee, Dae-Young Kim, Eun-Ji Choi, Eun-Hye Hur, Chan-Jeoung Park, Soseul Kim, Sangsoon Yoon, Kyeongcheon Jung, Kyoo-Hyung Lee
Journal: Blood (2015)